Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:CTSO NASDAQ:QTI NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.17-1.1%$2.57$1.98▼$20.00$17M-0.4651,421 shs33,862 shsCTSOCytosorbents$0.94-1.6%$0.99$0.71▼$1.61$59.83M1.28117,967 shs69,510 shsQTIQT Imaging$2.55+6.3%$2.09$0.35▼$0.84$69.19M-0.2183,964 shs20,460 shsTELATELA Bio$1.58-2.5%$1.80$0.86▼$3.26$62.59M0.8482,680 shs39,397 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies0.00%-1.72%-12.70%-13.05%-86.03%CTSOCytosorbents0.00%-2.81%-17.68%-13.90%-6.15%QTIQT Imaging+2.00%+2.82%+28.14%+207.60%+325.07%TELATELA Bio0.00%-0.63%-1.25%-7.06%-40.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.17-1.1%$2.57$1.98▼$20.00$17M-0.4651,421 shs33,862 shsCTSOCytosorbents$0.94-1.6%$0.99$0.71▼$1.61$59.83M1.28117,967 shs69,510 shsQTIQT Imaging$2.55+6.3%$2.09$0.35▼$0.84$69.19M-0.2183,964 shs20,460 shsTELATELA Bio$1.58-2.5%$1.80$0.86▼$3.26$62.59M0.8482,680 shs39,397 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies0.00%-1.72%-12.70%-13.05%-86.03%CTSOCytosorbents0.00%-2.81%-17.68%-13.90%-6.15%QTIQT Imaging+2.00%+2.82%+28.14%+207.60%+325.07%TELATELA Bio0.00%-0.63%-1.25%-7.06%-40.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.50Moderate Buy$22.83954.66% UpsideCTSOCytosorbents 2.50Moderate Buy$5.50486.04% UpsideQTIQT Imaging 0.00N/AN/AN/ATELATELA Bio 2.50Moderate Buy$4.50184.81% UpsideCurrent Analyst Ratings BreakdownLatest ALUR, QTI, TELA, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025ALURAllurion TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/21/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$19.92M0.84N/AN/A($30.08) per share-0.07CTSOCytosorbents$35.60M1.65N/AN/A$0.20 per share4.69QTIQT Imaging$4.00M17.31N/AN/A($1.91) per share-1.34TELATELA Bio$75.32M0.83N/AN/A$0.72 per share2.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.17N/AN/AN/A-25.58%-111.97%-29.00%11/6/2025 (Estimated)QTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%11/11/2025 (Estimated)TELATELA Bio-$37.84M-$1.12N/AN/AN/A-54.12%-329.48%-57.34%11/6/2025 (Estimated)Latest ALUR, QTI, TELA, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/11/2025Q2 2025TELATELA Bio-$0.18-$0.22-$0.04-$0.22$20.67 million$20.20 million8/7/2025Q2 2025CTSOCytosorbents-$0.07-$0.05+$0.02$0.03$9.79 million$9.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70CTSOCytosorbents1.242.341.96QTIQT ImagingN/A1.060.48TELATELA Bio4.143.192.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%CTSOCytosorbents32.87%QTIQT Imaging24.19%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%CTSOCytosorbents7.30%QTIQT Imaging75.40%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million6.02 millionOptionableCTSOCytosorbents22062.76 million58.18 millionOptionableQTIQT ImagingN/A27.13 million6.68 millionN/ATELATELA Bio12039.62 million37.75 millionOptionableALUR, QTI, TELA, and CTSO HeadlinesRecent News About These CompaniesTELA Bio’s Earnings Call Highlights Robust Growth5 hours ago | theglobeandmail.com200,000 Shares in TELA Bio, Inc. $TELA Acquired by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.com747,410 Shares in TELA Bio, Inc. $TELA Acquired by Velan Capital Investment Management LPAugust 31, 2025 | marketbeat.comStonepine Capital Management LLC Has $2.51 Million Stake in TELA Bio, Inc. $TELAAugust 26, 2025 | marketbeat.comTELA Bio (NASDAQ:TELA) Shares Down 2.9% - Here's What HappenedAugust 23, 2025 | marketbeat.comAroa Biosurgery Reports Strong Growth and Expands Product Range Amid Market ChallengesAugust 20, 2025 | msn.comTela Bio reports Q2 EPS (22c), consensus (19c)August 13, 2025 | msn.comTela Bio backs FY25 revenue view $85M-$88M, consensus $86.05MAugust 12, 2025 | msn.comTela Bio reiterates $85M–$88M 2025 revenue target as international expansion acceleratesAugust 12, 2025 | msn.comTELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comTELA Bio, Inc. (TELA) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comTELA Bio Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comTELA Bio Inc (TELA) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comTELA Bio Awards Inducement Equity Grants to New EmployeesAugust 10, 2025 | msn.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | globenewswire.comTELA Bio to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 23, 2025 | globenewswire.comTELA Bio to Announce Second Quarter 2025 Financial ResultsJuly 21, 2025 | globenewswire.comTELA Bio, Inc. (TELA) Latest Stock News & Headlines - Yahoo FinanceJuly 19, 2025 | finance.yahoo.comBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALUR, QTI, TELA, and CTSO Company DescriptionsAllurion Technologies NYSE:ALUR$2.16 -0.03 (-1.14%) Closing price 09/12/2025 03:55 PM EasternExtended Trading$2.18 +0.02 (+0.92%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Cytosorbents NASDAQ:CTSO$0.94 -0.01 (-1.55%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.94 +0.00 (+0.16%) As of 09/12/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.QT Imaging NASDAQ:QTI$2.55 +0.15 (+6.25%) As of 09/12/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.TELA Bio NASDAQ:TELA$1.58 -0.04 (-2.47%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
